zoledronic acid
Phase 3- Indications
- Complex Regional Pain Syndrome (CRPS)
Company intelligence / Profile preview
Thar Pharmaceuticals
Pittsburgh, Pennsylvania, United Statesexplorium.ai ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Thar Pharmaceuticals developed T121, a novel, non-opioid, oral formulation of zoledronic acid for the management of pain associated with complex regional pain syndrome. The company was acquired by Grunenthal before completing pivotal trials.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small moleculesoral formulations of IV drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Thar Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thar Pharmaceuticals.